Welcome to the SWYAPC website
The information on these pages is intended as a guide only. Whilst we endeavour to keep such information as up to date as possible, we make no claim as to its total accuracy or completeness. Information is liable to change, and such changes may not be mirrored in this site. We do not accept liability for any loss or damage resulting from use of this site or reliance on its content. External links lead to sites and pages over which we have no control, and which we cannot verify for accuracy or content. The inclusion of a link on this website should not be taken as an endorsement of the linked website, nor of the accuracy or quality of the information on such sites.
Ulipristal 5mg – Suspended March 2020 due to MHRA Safety Alert
Updates following the July 2020 Area Prescribing Committee Meeting
Red, Green Specialist Initiation and Green classifications
Remdesivir – Treatment for SARS-CoV-2 infection
Lorlatinib – Anaplastic lymphoma kinase (ALK)
Sodium zirconium cyclosilicate – Treatment of hyperkalaemia in adult patients
Azithromycin eye drops – Purulent bacterial conjunctivitis
Ceftazidime eye drops – Neisseria conjunctivitis
Natamycin eye drops – Treatment of keratitis due to a mould
Voriconazole eye drops – Candida keratitis
Danazol – Aplastic anaemia
Oxandrolone – Treatment of hypermetabolism in burns patients
Fremanezumab – Migraine
Green Specialist Initiation
Prasterone pessaries – Vulvar & Vaginal atrophy (VVA) in postmenopausal women with moderate to severe symptoms
Colesevelam – Bile acid malabsorption
Fexofenadine oral – Chronic spontaneous urticarial and angioedema (11 years and younger)
Fexofenadine oral – Chronic spontaneous urticarial and angioedema (12 years and over)
Shared Care Guidelines
Phenelezine removed – no longer available
Please refer to the NHS link regarding any information you may need in relation to COVID-19.
Flash Glucose Monitoring – Updated July 2019
We have been working with diabetes specialists in West Yorkshire and Harrogate to update our policies on flash glucose monitoring, following the publication of new guidance from NHS England, and to agree a single policy for all nine clinical commissioning groups.
A Flash Glucose commissioning policy for West Yorkshire and Harrogate has been approved and will start to implement the NHS England guidance regarding “Flash Glucose Monitoring: National Arrangements for Funding of Relevant Diabetes Patients.” The Diabetes Specialist Teams in local areas will be responsible for assessing whether patients meet the criteria in this guidance, starting flash glucose monitoring and ongoing review. The continued supply of the flash glucose monitoring sensors will transfer to the patients GP practice.
There are now available adult and paediatric patient agreement forms for Flash Glucose Monitoring here
Primary Care Antimicrobial Guidelines
On 16 January 2019 the South West Yorkshire Area Prescribing Committee approved local use of the new NICE/PHE managing common infections guidance.
This supersedes our local primary care guideline. As NICE/PHE have not completed all sections yet, we will continue to use local guidelines for those sections.
NICE/PHE – introduction to guidelines
NICE/PHE table – managing common infections (whole guideline)
Valproate Pregnancy Prevention Programme
Skin preparations (including emollients)
West Yorkshire Fire & Rescue Service has produced YouTube Videos for the public and patients and one for healthcare professionals warning that skin preparations can increase the risk of a fire developing. The YouTube videos have been added to the following sections of the website for information and discussion: Medicines Alerts and Safety Issues, Patient Information and Care Homes. There is also information on the Fire Service’s website. The MHRA has issued a press release.